On July 26, 2026, the FDA approved the first gene editing therapy for Duchenne muscular dystrophy, sending CRISPR Therapeutics, Editas Medicine, and other stocks sharply higher. This article analyzes the latest advances in gene editing, market prospects, and how investors can seize this US stock opportunity.